Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
about
Is There Evidence for Late Cognitive Decline in Chronic Schizophrenia?Aripiprazole: from pharmacological profile to clinical useCurrent Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive ReviewPreventing olanzapine-induced weight gain using betahistine: a study in a rat model with chronic olanzapine treatmentA Querying Method over RDF-ized Health Level Seven v2.5 Messages Using Life Science Knowledge ResourcesPriming of metabolic dysfunctions by prenatal immune activation in mice: relevance to schizophrenia.Rapid-onset clozapine-induced loss of glycaemic control: case reportTime-dependent changes and potential mechanisms of glucose-lipid metabolic disorders associated with chronic clozapine or olanzapine treatment in ratsThe health benefits and challenges of exercise training in persons living with schizophrenia: a pilot study.Metabolic syndrome among psychiatric outpatients with mood and anxiety disorders.The concomitant use of second-generation antipsychotics and long-term antiretroviral therapy may be associated with increased cardiovascular risk.Psychotropic medication use mediates the relationship between mood and anxiety disorders and obesity: findings from a nationally representative sample.Very low rates of screening for metabolic syndrome among patients with severe mental illness in Durban, South Africa.Ziprasidone hydrocloride: what role in the management of schizophrenia?Second generation antipsychotic-induced type 2 diabetes: a role for the muscarinic M3 receptor.Physical illness in patients with severe mental disorders. I. Prevalence, impact of medications and disparities in health care.Cardiovascular risk in a first-episode psychosis sample: a 'critical period' for prevention?Iloperidone, asenapine and lurasidone: a primer on their current status.Antipsychotics associated with the development of type 2 diabetes in antipsychotic-naïve schizophrenia patientsAssociation of psychiatric illness and obesity, physical inactivity, and smoking among a national sample of veterans.Lurasidone: a new drug in development for schizophrenia.Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism.Adapting SugarWatch to manage metabolic syndrome in a partial hospitalization program: a feasibility studySpleen: A new role for an old player?Efficacy of lifestyle interventions in physical health management of patients with severe mental illness.The effect of clozapine on premature mortality: an assessment of clinical monitoring and other potential confounders.Influence of the drug exposure definition on the assessment of the antipsychotic metabolic impact in patients initially treated with mood-stabilizers.XenomiRs and miRNA homeostasis in health and disease: evidence that diet and dietary miRNAs directly and indirectly influence circulating miRNA profiles.A Longitudinal Study of Relation between Side-effects and Clinical Improvement in Schizophrenia: Is There a Neuro-metabolic Threshold for Second Generation Antipsychotics?Microvascular dysfunction in schizophrenia: a case-control study.Obesity and Insulin Resistance Are the Central Issues in Prevention of and Care for Comorbidities.Association between the HTR2C rs1414334 C/G gene polymorphism and the development of the metabolic syndrome in patients treated with atypical antipsychotics.Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.Genetic risk factors for type 2 diabetes with pharmacologic intervention in African-American patients with schizophrenia or schizoaffective disorder.Berberine Alleviates Olanzapine-Induced Adipogenesis via the AMPKα-SREBP Pathway in 3T3-L1 Cells.The audacity of proteomics: a chance to overcome current challenges in schizophrenia research.Antipsychotics activate the TGFβ pathway effector SMAD3Treatment of co-morbid mental illness in primary care: how to minimize weight gain, diabetes, and metabolic syndrome.Unmet treatment needs in schizophrenia patients: is asenapine a potential therapeutic option?Atypical antipsychotic-induced weight gain: insights into mechanisms of action.
P2860
Q22252612-915B62F8-CD90-4EE6-8B64-3B13B9D3A2A5Q26778312-BF6D550C-55B4-46DB-8FEA-9B2C957614AAQ28079821-48BB0D88-2BB7-4477-A980-BFB3B8959FE4Q28541531-A717672F-57FE-4559-8843-49AE726116E2Q28604039-BD5E7DA4-97A2-4E2A-BE6A-1BF584F061A5Q30442468-7EA3824F-0CA6-4424-9969-F11B7A1ECE65Q30491691-05A5551E-A31D-4BA8-893D-4C7F9B5C1E7BQ33765864-EE8116F3-CB9E-43D3-828A-F21E45AE14AEQ33772123-E4CCADDE-A9FE-4E61-8FE5-76F73F42BFECQ33836586-A23766C8-88EF-44FA-9407-641E6FA5B555Q33849136-5DF35595-5A67-4215-876F-A1DF4560FEFBQ34049910-E3205536-2AE7-4E26-9FF4-ADDF481C0137Q34109049-5BA72A65-A36F-4E80-9389-5FE008AAD6A5Q34357931-9471A157-EC30-49B3-80D0-D0408DD139C7Q34376884-9CB1612A-DA7A-46F5-8869-CF71239E7C43Q34623350-0CF1DF5B-BA2E-4CA5-A080-61FF8CAF8C9DQ34634393-D1F3C497-8F75-4314-B683-D1784CB63405Q34641024-784B450F-506C-4473-98F1-43461802DC46Q34661651-FFA4F7CF-8ED0-425A-A5DC-62CD8AACCDC8Q34981408-526B253B-5C1E-4560-A967-2FED83ADEEF3Q35005165-6E35AF64-6485-45D2-930E-FE5E9463AAADQ35115972-9FC39878-A543-4B78-8DC1-6C20F7A487F9Q35189111-9D4DE13A-1A00-4B64-AC6B-483FB04FA615Q35235925-EA1F60D7-4344-4A7F-851A-66F8C0924566Q35290463-148F87D5-CADE-4C9F-809A-75E8FB4202BDQ35369635-9BFF11EA-6810-48DB-9E11-9681563AA9BBQ36088018-8758071A-ED3A-4204-92FF-2ACA9610BCF0Q36631208-4F726EF9-B75E-44D7-AAEC-0BED72341456Q36832340-AA27EC33-33E0-493E-955D-2B332E464ACBQ36848290-529FBD4A-0F97-4A99-ACD0-4AE378A16696Q37081549-0A193531-8931-4994-9EF6-7ED7A0787913Q37087294-AFED682A-1230-4D45-AEA7-06FCC8BAE930Q37110540-C4B2DC2D-E8F0-414A-B470-07F415E0521DQ37365437-E71EF2EB-501F-430D-8EBE-4669A6AE7A4EQ37465547-98DD41E8-F43A-4D9D-9872-CDC820E35405Q37636121-EA43B9D0-939D-44AE-A2FA-77D6E83AD0EDQ37710090-ABEE514F-D340-4724-BE0D-541B320F950FQ37889896-2E809017-4153-429A-80F2-7C6A4ADBCD1FQ37896627-A355B452-7F00-4F34-BCCB-DF3A64E27EA6Q37963571-F79483E8-4EFE-4546-B2AA-CB45E57964B6
P2860
Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
description
2009 nî lūn-bûn
@nan
2009 թուականի Մարտին հրատարակուած գիտական յօդուած
@hyw
2009 թվականի մարտին հրատարակված գիտական հոդված
@hy
2009年の論文
@ja
2009年論文
@yue
2009年論文
@zh-hant
2009年論文
@zh-hk
2009年論文
@zh-mo
2009年論文
@zh-tw
2009年论文
@wuu
name
Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
@ast
Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
@en
Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
@nl
type
label
Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
@ast
Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
@en
Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
@nl
prefLabel
Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
@ast
Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
@en
Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
@nl
P2093
P1476
Which comes first: atypical antipsychotic treatment or cardiometabolic risk?
@en
P2093
P2860
P304
P356
10.1111/J.1600-0447.2008.01334.X
P407
P577
2009-03-01T00:00:00Z